1. Home
  2. COLL vs RLJ Comparison

COLL vs RLJ Comparison

Compare COLL & RLJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • RLJ
  • Stock Information
  • Founded
  • COLL 2002
  • RLJ 2011
  • Country
  • COLL United States
  • RLJ United States
  • Employees
  • COLL N/A
  • RLJ N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • RLJ Real Estate Investment Trusts
  • Sector
  • COLL Health Care
  • RLJ Real Estate
  • Exchange
  • COLL Nasdaq
  • RLJ Nasdaq
  • Market Cap
  • COLL 958.8M
  • RLJ 1.1B
  • IPO Year
  • COLL 2015
  • RLJ 2011
  • Fundamental
  • Price
  • COLL $37.03
  • RLJ $7.26
  • Analyst Decision
  • COLL Strong Buy
  • RLJ Hold
  • Analyst Count
  • COLL 4
  • RLJ 6
  • Target Price
  • COLL $44.25
  • RLJ $9.35
  • AVG Volume (30 Days)
  • COLL 380.6K
  • RLJ 1.6M
  • Earning Date
  • COLL 08-07-2025
  • RLJ 08-07-2025
  • Dividend Yield
  • COLL N/A
  • RLJ 8.29%
  • EPS Growth
  • COLL N/A
  • RLJ N/A
  • EPS
  • COLL 1.06
  • RLJ 0.20
  • Revenue
  • COLL $707,007,000.00
  • RLJ $1,367,020,000.00
  • Revenue This Year
  • COLL $20.47
  • RLJ $0.81
  • Revenue Next Year
  • COLL $2.91
  • RLJ $1.59
  • P/E Ratio
  • COLL $35.07
  • RLJ $36.35
  • Revenue Growth
  • COLL 22.61
  • RLJ 1.40
  • 52 Week Low
  • COLL $23.23
  • RLJ $6.16
  • 52 Week High
  • COLL $42.29
  • RLJ $10.84
  • Technical
  • Relative Strength Index (RSI)
  • COLL 69.53
  • RLJ 43.42
  • Support Level
  • COLL $29.70
  • RLJ $6.88
  • Resistance Level
  • COLL $38.24
  • RLJ $7.46
  • Average True Range (ATR)
  • COLL 1.23
  • RLJ 0.22
  • MACD
  • COLL 0.71
  • RLJ -0.03
  • Stochastic Oscillator
  • COLL 87.29
  • RLJ 27.67

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About RLJ RLJ Lodging Trust of Beneficial Interest $0.01 par value

RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.

Share on Social Networks: